Car-T Lymphoma London Ltd Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 14034441

Car-T Lymphoma London Ltd

Filleted Unaudited Financial Statements

31 March 2025

Car-T Lymphoma London Ltd

Financial Statements

Year ended 31 March 2025

Contents	Page

Statement of financial position	1

Notes to the financial statements	3

Car-T Lymphoma London Ltd

Statement of Financial Position

31 March 2025

	2025	2024
Note	£	£

Fixed assets

Tangible assets	5	3,740	5,774

Current assets

Debtors	6	32,824	6,666
Cash at bank and in hand		9,298	1,235
		--------	-------
		42,122	7,901

Creditors: amounts falling due within one year	7	13,564	11,752
		--------	--------
Net current assets/(liabilities)		28,558	( 3,851)
		--------	-------
Total assets less current liabilities		32,298	1,923

Provisions	935	1,444
	--------	-------
Net assets	31,363	479
	--------	-------

Capital and reserves

Called up share capital	1	1
Profit and loss account	31,362	478
	--------	----
Shareholders funds	31,363	479
	--------	----

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Car-T Lymphoma London Ltd

Statement of Financial Position (continued)

31 March 2025

These financial statements were approved by the board of directors and authorised for issue on 31 December 2025 , and are signed on behalf of the board by:

Dr R Sanderson
Director

Company registration number: 14034441

Car-T Lymphoma London Ltd

Notes to the Financial Statements

Year ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Flat 55 Errington House, 4 Brigade Mews, London, United Kingdom, SE1 0GN.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for services rendered, net of discounts.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

	Equipment	-	33% straight line

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly.

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.

4. Employee numbers

The average number of persons employed by the company during the year, including the director, amounted to 1.

5. Tangible assets

	Equipment
	£
Cost
At 1 April 2024	7,710
Additions	1,392
Disposals	( 2,286)
	-------
At 31 March 2025	6,816
	-------
Depreciation
At 1 April 2024	1,936
Charge for the year	2,219
Disposals	( 1,079)
	-------
At 31 March 2025	3,076
	-------
Carrying amount
At 31 March 2025	3,740
	-------
At 31 March 2024	5,774
	-------

6. Debtors

	2025	2024
	£	£
Trade debtors	2,940	–
Other debtors	29,884	6,666
	--------	-------
	32,824	6,666
	--------	-------

7. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	1,153	125
Corporation tax	9,066	2,396
Other creditors	3,345	9,231
	--------	--------
	13,564	11,752
	--------	--------

8. Director's advances, credits and guarantees

During the year, the Director was advanced £27,423 (2024: 24,620),repayments of £4,801 (2024: £17,910) were made and the balance owed by the director at the year end was £29,184 (2024: £6,206). Interest of £356 was charged on this loan at a rate of 2.25%.